Clinical Trials Directory

Trials / Completed

CompletedNCT02906553

The Role of Nitric Oxide in Cognition in Schizophrenia

The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study (Nitric Oxide in Cognition)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
19 (actual)
Sponsor
King's College London · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the role of the Nitric Oxide system in cognition in patients with schizophrenia. Participants will be randomised to 2 equal groups and receive either the Nitric Oxide donor molecule glyceryl trinitrate, or a placebo. Performance on several cognitive tasks will be assessed.

Detailed description

Nitric oxide \[NO\] is a gaseous neurotransmitter substance found in the brain. Nitric oxide is integrated with the glutamate system. Glutamate has received considerable attention as an important factor in the cognitive distortions and cognitive impairments that underlie schizophrenia. Deficits in glutamate in schizophrenia may impact upon cognition via the NO system, as glutamate receptors signal by way of NO. Here the investigators aim to extend knowledge of glutamate-NO systems by directly examining the role of NO in cognition in patients with psychosis. We aim to assess the role of the NO system in cognition, downstream of glutamate and before patients are started on any anti-psychotic medication which perturb brain neurochemistry. The primary outcome measure is change in a particular style of cognition referred to as 'jumping to conclusions' following the administration of a potent Nitric Oxide donor molecule \[glyceryl trinitrate (GTN)\], under placebo-controlled, double-blind conditions. This will shed light on the direct role of NO in cognition in psychosis, beyond the glutamate system.

Conditions

Interventions

TypeNameDescription
DRUGGlyceryl Trinitrate
DRUGPlacebo

Timeline

Start date
2016-09-01
Primary completion
2019-04-01
Completion
2019-04-01
First posted
2016-09-20
Last updated
2019-08-13

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02906553. Inclusion in this directory is not an endorsement.